MAP2K7 and cancer: VS-6766 (Avutometinib) is a dual RAF–MEK inhibitor that showed good therapeutic activity against KRAS G12V mutation and is under clinical evaluation (NCT03875820, Phase I, NCT04625270, Phase II) for different types of KRAS-mutated cancers [39].